ADC + checkpoint inhibitor
An ADC kills tumour cells in a way that alerts the immune system; a checkpoint inhibitor lets the immune system finish the job.
Proven in urothelial cancer (EV-302: enfortumab vedotin + pembrolizumab, OS HR 0.47) and TNBC (ASCENT-04: sacituzumab govitecan + pembrolizumab, PFS HR 0.65, approved 2026). TROPION-Breast05 (Dato-DXd + durvalumab) and multiple lung trials follow. Overlapping pneumonitis risk with DXd ADCs needs care.
Pages like this
not linked directly; found by shared links- PairingEnfortumab vedotin + pembrolizumab across the bladder cancer continuum
Shares EV-302 / KEYNOTE-A39, Enfortumab vedotin, Bladder & urothelial cancer, Pembrolizumab.
- PersonJae Lyun Lee
Shares EV-302 / KEYNOTE-A39, Enfortumab vedotin, Bladder & urothelial cancer, Pembrolizumab.
- PairingRadiotherapy + immunotherapy
Shares An oncology patent pool for combination trials across companies, cGAS–STING innate sensing, Pembrolizumab, Immune checkpoint inhibitors.
- Key paperEV-302: enfortumab vedotin plus pembrolizumab replaces chemotherapy as first treatment for advanced bladder cancer
Shares EV-302 / KEYNOTE-A39, Enfortumab vedotin, Bladder & urothelial cancer, Pembrolizumab.
- TargetNectin-4
Shares EV-302 / KEYNOTE-A39, Enfortumab vedotin, Bladder & urothelial cancer, Antibody-drug conjugate (ADC).
- TrialSCARLET (SWOG S2212)
Shares Neoadjuvant ADC + IO replacing anthracycline chemotherapy in TNBC, Pembrolizumab, Triple-negative breast cancer (TNBC).
- PersonShilpa Gupta
Shares Enfortumab vedotin, Bladder & urothelial cancer, Pembrolizumab.
- RoadmapTROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET
Shares TROPION-Breast05, ASCENT-04 / KEYNOTE-D19, Sacituzumab govitecan, Bladder & urothelial cancer.